Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bio-Thera Solutions Ltd.

Latest From Bio-Thera Solutions Ltd.

Bio-Thera And Macter Partner On Bevacizumab

Bio-Thera Solutions has struck a deal with Macter International for rights to its BAT1706 biosimilar rival to Avastin (bevacizumab) in Pakistan and Afghanistan.

Deals Biosimilars

Bio-Thera Secures FDA Approval For Sandoz-Partnered Bevacizumab Biosimilar

Bio-Thera has received US Food and Drug Administration approval for its bevacizumab biosimilar, marking the second biosimilar drug researched, developed and manufactured by a Chinese pharmaceutical company to receive US approval.

Approvals Biosimilars

Bio-Thera Delivers Positive Phase III Results For Stelara Biosimilar

Bio-Thera has announced positive Phase III results for its ustekinumab biosimilar candidate BAT2206, demonstrating that the product is highly similar to originator Stelara in patients with moderate to severe plaque psoriasis. 

Biosimilars Clinical Trials

Biogen, Bio-Thera Shake Hands On US Actemra Settlement

Biogen, Bio-Thera Solutions and Roche have announced a settlement has been reached allowing patent-infringement litigation over Actemra to be dismissed.

Intellectual Property Legal Issues
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Biotech Biopharmaceutical Co., Ltd.